Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting
Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at the American Society of Clinical […]
Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at the American Society of Clinical […]
In connection with the offering to acquire newly issued shares in Isofol and the listing on Nasdaq First North Premier
For a complete press release follow the link http://isofol.se/en/ipo/ For additional information, please contact: Anders Rabbe, Managing Director, Isofol Mob: +46 70
Isofol Medical AB announced today that the study ISO-MTX-003 evaluating Modufolin® as rescue therapy (after two cycles of HDMTX treatment)
Isofol Medical AB (publ) announces today that its largest shareholder and co-founder, Bengt Gustavsson, now acquired circa 16 000 shares
Isofol Medical AB (publ) announces that its Chairman of the Board, Jan-Eric Österlund, now acquired 15,000 shares in Isofol to
In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we are pleased to invite you
In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we are pleased to invite you
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,